Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis.
Saved in:
| Title: | Efficacy and Safety of Biosimilar CT-P47 Versus Reference Tocilizumab: 1-Year Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study in Patients with Rheumatoid Arthritis. |
|---|---|
| Authors: | Burmester, Gerd1 (AUTHOR), Trefler, Jakub2 (AUTHOR), Racewicz, Artur3 (AUTHOR), Jaworski, Janusz4 (AUTHOR), Zielińska, Agnieszka5 (AUTHOR), Krogulec, Marek6 (AUTHOR), Jeka, Sławomir7 (AUTHOR), Wojciechowski, Rafał8 (AUTHOR), Kolossa, Katarzyna9 (AUTHOR), Dudek, Anna10 (AUTHOR), Krajewska-Włodarczyk, Magdalena11 (AUTHOR), Hrycaj, Paweł12 (AUTHOR), Klimiuk, Piotr Adrian13 (AUTHOR), Kim, SungHyun14 (AUTHOR), Suh, JeeHye14 (AUTHOR), Yang, GoEun14 (AUTHOR), Kim, YunAh14 (AUTHOR), Jung, YooBin14 (AUTHOR), Park, GaHee14 (AUTHOR), Smolen, Josef S.15 (AUTHOR) josef.smolen@meduniwien.ac.at |
| Source: | Clinical Drug Investigation. Aug2025, Vol. 45 Issue 8, p551-563. |
| Database: | SPORTDiscus with Full Text |
Be the first to leave a comment!
